A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.

MLA

Hughes, Brett G. M., et al. “A Phase 2 Open-Label Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (EMPOWER-CSCC-1): Final Long-Term Analysis of Groups 1, 2, and 3, and Primary Analysis of Fixed-Dose Treatment Group 6.” Journal of the American Academy of Dermatology, vol. 92, no. 1, Jan. 2025, pp. 68–77. EBSCOhost, https://doi.org/10.1016/j.jaad.2024.06.108.

APA

Hughes, B. G. M., Guminski, A., Bowyer, S., Migden, M. R., Schmults, C. D., Khushalani, N. I., Chang, A. L. S., Grob, J.-J., Lewis, K. D., Ansstas, G., Day, F., Ladwa, R., Stein, B. N., Muñoz Couselo, E., Meier, F., Hauschild, A., Schadendorf, D., Basset-Seguin, N., Modi, B., … Rischin, D. (2025). A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. Journal of the American Academy of Dermatology, 92(1), 68–77. https://doi.org/10.1016/j.jaad.2024.06.108

Chicago

Hughes, Brett G M, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults, Nikhil I Khushalani, Anne Lynn S Chang, et al. 2025. “A Phase 2 Open-Label Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (EMPOWER-CSCC-1): Final Long-Term Analysis of Groups 1, 2, and 3, and Primary Analysis of Fixed-Dose Treatment Group 6.” Journal of the American Academy of Dermatology 92 (1): 68–77. doi:10.1016/j.jaad.2024.06.108.